Endologix Inc. Completes Enrollment in PEVAR Randomized Trial

IRVINE, Calif., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the completion of patient enrollment in the Company's prospective, multicenter, randomized clinical trial of a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair (EVAR). Endologix is the first Company to receive United States Food and Drug Administration (FDA) approval of an Investigational Device Exemption (IDE) to evaluate percutaneous EVAR (PEVAR) for the treatment of abdominal aortic aneurysms (AAAs). The Company expects to submit a supplement to its premarket approval application (PMA) with the primary endpoint results to request FDA approval for this broadened PEVAR indication during the second quarter of 2012.